# A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis

> **NCT02279563** · PHASE2 · UNKNOWN · sponsor: **Apotex Inc.** · enrollment: 595 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray
- **DRUG:** Dymista™ Nasal Spray
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02279563
- **Lead sponsor:** Apotex Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2014-02
- **Final completion:** —
- **Target enrollment:** 595 (ACTUAL)
- **Last updated:** 2014-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279563, "A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02279563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*